Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1346.676
- +17.561+1.32%
Close Jan 17 16:00 ET
1361.103High1338.138Low
1344.644Open1329.115Pre Close18.87MVolume7Rise65.80P/E (Static)1.39BTurnover--Flatline1.51%Turnover Ratio161.40BMarket Cap3Fall159.30BFloat Cap
Constituent Stocks: 10Top Rising: A+1.82%
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Monday, 13th January at 9:00 am
• Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia
• Achieved in vivo editing of liver cells in non-human primates and in vivo deliver...
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
No comment yet